Leukapheresis Market Size & Share 2024 - 2032

Leukapheresis Market Size

Leukapheresis market was valued at around USD 281.8 million in 2023 and is estimated to grow at 12.7% CAGR from 2024 to 2032. Leukapheresis is a specialized medical procedure designed to extract and collect white blood cells (leukocytes) from a patient's bloodstream. The process involves drawing blood from the patient, which is then filtered through a machine to isolate the white blood cells. Subsequently, the other blood components, such as red blood cells and platelets, are reintroduced into the patient's system.

The escalating incidence of blood cancer stands out as a primary catalyst propelling the market's growth. For context, a report by the World Cancer Research Fund International (WCRF) highlighted that in 2022, there were 487,294 global diagnoses of blood cancer. This included 278,120 cases in males and 209,174 in females. Such statistics emphasize the surging demand for effective treatment modalities. Technologies like leukapheresis are pivotal in blood cancer management, adeptly removing abnormal white blood cells and enhancing patient care and treatment results.
 

Additionally, the market is buoyed by innovations in leukapheresis devices and methodologies, heightened R&D focus on cell-based therapies and immunotherapy, and supportive government policies and initiatives.
 

Leukapheresis Market Trends

Advancements in leukapheresis devices and procedures have markedly transformed the landscape of blood cancer treatment and management. As the prevalence of blood cancers continues to rise globally, these innovations are becoming increasingly vital. The latest developments in leukapheresis technology not only enhance the precision and efficiency of white blood cell separation but also improve patient safety and comfort.
 

• Modern leukapheresis devices leverage advanced centrifugation and cell separation technologies, ensuring a higher yield and purity of leukocytes while minimizing the loss of other blood components. The latest models, equipped with sophisticated automation and user-friendly interfaces, significantly reduce the need for manual intervention, thereby boosting efficiency and curtailing the risk of human error.
   
• For instance, the Terumo BCT Spectra Optia is an advanced apheresis system that enhances leukapheresis efficiency and safety by integrating real-time monitoring and automated adjustments for critical parameters like blood flow rates and anticoagulant levels, ensuring higher yields and better patient outcomes.
   
• Advancements in filtration technology and centrifuge design have markedly boosted the efficiency of leukocyte separation. For instance, MACSQuant Tyto Cell Sorter introduced by Miltenyi Biotec in January 2020 offers heightened precision, reducing contamination risks and elevating cell purity.
   
• Additionally, advanced sensors integrated into leukapheresis devices offer precise control over the separation process. These sensors track parameters such as flow rates, pressure, and cell concentration, facilitating real-time adjustments to uphold optimal conditions during the procedure, fueling notable market growth.
   

Leukapheresis Market Analysis

Based on product, the market is segmented into disposables and devices. Further, devices segment is bifurcated into centrifugal devices, membrane separators, and other devices. The disposables segment of the market is forecasted to reach USD 502.6 million by 2032.
 

• Disposable leukapheresis sets and tubing reduce the risk of cross-contamination among patients. Each set is used a single time before being discarded, effectively averting the potential transmission of infections or other contaminants.
   
• The use of disposables eliminates the need for complex and time-consuming sterilization processes associated with reusable equipment. This simplifies the workflow and reduces the potential for human error in maintaining equipment sterility.
   
• Moreover, disposable components are designed for single-use, which streamlines the setup and teardown of the leukapheresis procedure. This convenience helps in reducing preparation time and ensures that the equipment is always in optimal condition. This efficiency and reliability not only enhance procedural workflows but also contribute to higher standards of patient safety and care, subsequently driving growth in the market.

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the leukapheresis market is segmented into therapeutic and research. Further, therapeutic segment is divided into hematology disorders, autoimmune diseases, and other therapeutic applications. Research segment is further bifurcated into cancer research, immunology research, and other research applications. The therapeutic segment accounted for dominating revenue of USD 155.5 million in 2023.
 

• Leukapheresis allows for the selective collection of specific types of white blood cells, such as leukocytes or stem cells, tailored to the patient's therapeutic needs. This targeted therapeutic approach improves the efficacy of treatments such as immunotherapy or stem cell transplantation, increasing their adoption.
   
• Additionally, therapeutic apheresis using leukapheresis is effective in managing autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. By removing autoantibodies and immune complexes from the blood, often alongside plasma exchange, leukapheresis helps to decrease inflammation and mitigate disease activity.
   
• Further, by collecting a high concentration of desired cells, leukapheresis enhances the effectiveness of therapies, including those for cancer treatment such as CAR-T cell therapy and autoimmune disorders. The ability to concentrate and purify cells leads to more potent and focused treatments. This combination of benefits drives the revenue growth in the therapeutic segment.
   

Based on end-use, the leukapheresis market is bifurcated into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies, and hospital and transfusion centers. The hospital and transfusion centers segment is forecasted to reach USD 297.7 million by 2032.
 

• Leukapheresis allows hospitals and transfusion centers to efficiently collect and separate leukocytes, which are crucial for various treatments, including cancer immunotherapy and regenerative medicine. This efficiency supports timely and effective treatment plans.
   
• In transfusion centers, leukapheresis improves the quality of blood products by separating and removing leukocytes from donated blood. This results in higher-quality blood components and reduces the risk of transfusion-associated complications.
   
• Further, leukapheresis provides valuable samples for research in immunology and hematology, aiding in the development of new treatments and understanding of various diseases. Hospitals and research centers utilize these samples to advance medical knowledge and innovation, thereby driving continued progress and growth in the field of medical research and therapy.

By 2032, the U.S. leukapheresis market is projected to reach USD 280.5 million.
 

• The U.S. is a leader in the development and adoption of cutting-edge leukapheresis technologies, including sophisticated apheresis equipment with advanced automation and real-time monitoring capabilities.
   
• The rising incidence of blood cancers in the U.S. is propelling significant market growth. For example, data from the Leukemia & Lymphoma Society indicates that in 2023, 184,720 individuals in the U.S. were diagnosed with leukemia, lymphoma, or myeloma. These diagnoses represented 9.4% of the 1,958,310 new cancer cases in the U.S., highlighting the substantial impact of these cancers and the pressing need for enhanced treatments and support.
   

From 2024 to 2032, the UK leukapheresis market is poised for notable growth.
 

• The rising rates of cancer and autoimmune diseases, including rheumatoid arthritis and type 1 diabetes, are driving the demand for leukapheresis procedures in the UK. This demand is further bolstered by the growing embrace of cell-based therapies and personalized medicine.
   
• For instance, a 2020 study by the National Institute for Health and Care Excellence (NICE) revealed that about 1% of the UK population, or 67.1 million people, have confirmed cases of rheumatoid arthritis. This prevalence has led to a heightened demand for leukapheresis procedures to tackle complex autoimmune conditions, fueling market growth.
   

Japan's leukapheresis market is set for lucrative growth between 2024 and 2032.
 

• Japan's robust healthcare system readily adopts advanced leukapheresis technologies. The nation's commitment to high patient care standards ensures the seamless integration of these cutting-edge devices into medical practice.
   
• Moreover, the Japanese government actively champions medical technology advancements, offering research funding and incentives to spur innovation in the healthcare sector.
   

The leukapheresis market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• With a strong commitment to enhancing its healthcare infrastructure, Saudi Arabia is not only modernizing its facilities but also integrating advanced medical technologies like leukapheresis devices to elevate patient care and treatment results.
   

Leukapheresis Market Share

The leukapheresis sector is very competitive, with a mix of major global players and smaller and medium-sized companies. Success in this market depends on the continuous introduction of new devices with advanced technologies like automation and real-time monitoring. Leading companies shape market trends through significant R&D investments and strategic actions such as alliances, acquisitions, and mergers. Smaller firms often focus on niche segments or specialized applications to compete with established players. These dynamics drive rapid market evolution and growth.
 

Leukapheresis Market Companies

Some of the eminent market participants operating in the leukapheresis industry include:

• Asahi Kasei Corporation
• Beijing ZKSK Technology Co., Ltd.
• Baxter International Inc.
• Cardinal Health, Inc.
• Fresenius SE & Co. KGaA
• Guangzhou DaJi Medical Science and Technology Co., Ltd.
• Haemonetics Corporation
• Macopharma
• Medica SPA
• Miltenyi Biotec
• Mitra Industries Private Limited
• Nikkiso Co. Ltd.
• Puriblood Medical Co. Ltd.
• SB-Kawasumi Laboratories, Inc.
• Terumo BCT, Inc.
   

Leukapheresis Industry News:

• In February 2024, Miltenyi Biotec expanded into India by opening the Miltenyi Innovation and Technology Center, establishing it as a Center of Excellence for Cell and Gene Therapy (CGT). This expansion underscores Miltenyi Biotec's dedication to advancing CGT and fostering innovation in biotechnological sector.
   

The leukapheresis market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Disposables   
• Devices        
  • Centrifugal devices
  • Membrane separators
  • Other devices

Market, By Application

• Therapeutic  
  • Hematology disorders
  • Autoimmune diseases
  • Other therapeutic applications
• Research      
  • Cancer research
  • Immunology research
  • Other research applications

Market, By End-use

• Blood component providers and blood centers
• Academic and research institutes
• Pharmaceutical and biotechnology companies
• Hospital and transfusion centers

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa